{"id":"brentuximab-vedotin-for-injection","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of activated lymphocytes, including Hodgkin and non-Hodgkin lymphoma cells. Brentuximab vedotin is a monoclonal antibody-drug conjugate that binds to CD30 and delivers the toxic agent monomethyl auristatin E (MMAE) to these cells, leading to cell death.","oneSentence":"Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:03.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Systemic anaplastic large cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT05481437","phase":"","title":"A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-01","conditions":"Hodgkin Lymphoma","enrollment":8},{"nctId":"NCT01578499","phase":"PHASE3","title":"A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-06-11","conditions":"Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Brentuximab Vedotin for Injection","genericName":"Brentuximab Vedotin for Injection","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells. Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}